Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Octavio Burgués"'
Autor:
Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lameirinhas, Octavio Burgués, Cristina Hernando, María Teresa Martínez, Federico Rojo, Begoña Bermejo, Marta Tapia, Juan Antonio Carbonell-Asins, Carlos Javier Peña, Ana Lluch, Juan Miguel Cejalvo, Eduardo Tormo, Pilar Eroles
Publikováno v:
Cell Death Discovery, Vol 10, Iss 1, Pp 1-13 (2024)
Abstract Despite progress in breast cancer treatment, a significant portion of patients still relapse because of drug resistance. The involvement of microRNAs in cancer progression and chemotherapy response is well established. Therefore, this study
Externí odkaz:
https://doaj.org/article/3a1b2fe95e2d47d181a620741b4f85f7
Autor:
Elisa I. Rivas, Jenniffer Linares, Melissa Zwick, Andrea Gómez-Llonin, Marc Guiu, Anna Labernadie, Jordi Badia-Ramentol, Anna Lladó, Lídia Bardia, Iván Pérez-Núñez, Carolina Martínez-Ciarpaglini, Noelia Tarazona, Anna Sallent-Aragay, Marta Garrido, Toni Celià-Terrassa, Octavio Burgués, Roger R. Gomis, Joan Albanell, Alexandre Calon
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-16 (2022)
A substantial proportion of HER2+ breast cancer patients do not benefit from HER2-targeted therapy. Here, the authors identify a population of cancer-associated fibroblasts involved in the suppression of trastuzumab-induced ADCC that can be pharmacol
Externí odkaz:
https://doaj.org/article/5a2417c908e3473699f39e6e2bb007ca
Autor:
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 4, p 3601 (2023)
Due to the lack of specific targets, cytotoxic chemotherapy still represents the common standard treatment for triple-negative breast patients. Despite the harmful effect of chemotherapy on tumor cells, there is evidence that treatment could modulate
Externí odkaz:
https://doaj.org/article/58fb6b02a97b494abfaa2932b5aa3d4a
Autor:
Sonia Pernas, Patricia Villagrasa, Ana Vivancos, Maurizio Scaltriti, Jordi Rodón, Octavio Burgués, Paolo Nuciforo, Jordi Canes, Laia Paré, Marta Dueñas, Maria Vidal, Juan Miguel Cejalvo, Antonia Perelló, Antonio Llommbard-Cussac, Joan Dorca, Alvaro Montaño, Tomás Pascual, Mafalda Oliveira, Gloria Ribas, Inmaculada Rapado, Aleix Prat, Eva Ciruelos
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundThe SOLTI-1301 AGATA study aimed to assess the feasibility of a multi-institutional molecular screening program to better characterize the genomic landscape of advanced breast cancer (ABC) and to facilitate patient access to matched-targete
Externí odkaz:
https://doaj.org/article/bc3ebc5d1a36401a91652476aa999c1a
Autor:
Birlipta Pattanayak, Ana Lameirinhas, Sandra Torres-Ruiz, Octavio Burgués, Ana Rovira, María Teresa Martínez, Marta Tapia, Sandra Zazo, Joan Albanell, Federico Rojo, Begoña Bermejo, Pilar Eroles
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 21, p 13292 (2022)
Treatment for the HER2+ breast cancer subtype is still unsatisfactory, despite breakthroughs in research. The discovery of various new molecular mechanisms of transcription factors may help to make treatment regimens more effective. The transcription
Externí odkaz:
https://doaj.org/article/4590e0898da442fa9094005b3e9fd4d3
Autor:
Begoña Pineda, Angel Diaz-Lagares, José Alejandro Pérez-Fidalgo, Octavio Burgués, Inés González-Barrallo, Ana B. Crujeiras, Juan Sandoval, Manel Esteller, Ana Lluch, Pilar Eroles
Publikováno v:
Clinical Epigenetics, Vol 11, Iss 1, Pp 1-11 (2019)
Abstract Background Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) varies between 30 and 40% approximately. To provide further insight into the prediction of pCR, we evaluated the rol
Externí odkaz:
https://doaj.org/article/7f903dd11caf4c39804ae0860ef80b4b
Autor:
Raul Gomez, Miguel Á. Tejada, Víctor Rodríguez-García, Octavio Burgués, Ana I. Santos-Llamas, Andrea Martínez-Massa, Antonio Marín-Montes, Juan J. Tarín, Antonio Cano
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 3, p 1742 (2022)
The receptor activator of nuclear factor kappa B (RANK) is becoming recognized as a master regulator of tumorigenesis, yet its role in gynecological cancers remains mostly unexplored. We investigated whether there is a gradation of RANK protein and m
Externí odkaz:
https://doaj.org/article/164be5e6635d4c23866b1da38c282cb7
Autor:
Birlipta Pattanayak, Iris Garrido-Cano, Anna Adam-Artigues, Eduardo Tormo, Begoña Pineda, Paula Cabello, Elisa Alonso, Begoña Bermejo, Cristina Hernando, María Teresa Martínez, Ana Rovira, Joan Albanell, Federico Rojo, Octavio Burgués, Juan Miguel Cejalvo, Ana Lluch, Pilar Eroles
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Downregulation of miR-33b has been documented in many types of cancers and is being involved in proliferation, migration, and epithelial–mesenchymal transition (EMT). Furthermore, the enhancer of zeste homolog 2-gene (EZH2) is a master regulator of
Externí odkaz:
https://doaj.org/article/116915f38b83493fb827155096227e7d
Autor:
Raúl Gómez, Ana Castro, Jessica Martínez, Víctor Rodríguez-García, Octavio Burgués, Juan J. Tarín, Antonio Cano
Publikováno v:
International Journal of Molecular Sciences, Vol 19, Iss 7, p 1848 (2018)
The system integrated by the receptor activator of nuclear factor kappa B (RANK) and its ligand, RANKL, modulates the role of hormones in the genesis and progression of breast tumors. We investigated whether the expression of RANK was related with cl
Externí odkaz:
https://doaj.org/article/83af17792bcb447db7f7bfd44b6311b0
Autor:
Marta Maia Boscá-Watts, Andrea Marco-Marqués, Ester Savall-Núñez, Ana Artero-Fullana, Bernardo Lanza-Reynolds, Verónica Andrade-Gamarra, Víctor Puglia-Santos, Octavio Burgués-Gasión, Francisco Mora-Miguel
Publikováno v:
Revista Espanola de Enfermedades Digestivas, Vol 108, Iss 8, Pp 516-520
Introduction: Strongyloides has been shown to infrequently mimic inflammatory bowel disease (IBD) or to disseminate when a patient with IBD and unrecognized strongyloides is treated with immunosupression. Case report: A man from Ecuador, living in Sp
Externí odkaz:
https://doaj.org/article/b133b6b81cc2477f989fc1d5959875a9